Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Ligand Pharmaceuticals (LGNYZ) over the last 16 years, with Q3 2025 value amounting to $409.6 million.

  • Ligand Pharmaceuticals' Cash from Financing Activities rose 64372.73% to $409.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $440.3 million, marking a year-over-year increase of 43648.32%. This contributed to the annual value of $97.1 million for FY2024, which is 26204.48% up from last year.
  • According to the latest figures from Q3 2025, Ligand Pharmaceuticals' Cash from Financing Activities is $409.6 million, which was up 64372.73% from $15.0 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Cash from Financing Activities registered a high of $409.6 million during Q3 2025, and its lowest value of -$170.4 million during Q1 2022.
  • In the last 5 years, Ligand Pharmaceuticals' Cash from Financing Activities had a median value of -$385000.0 in 2021 and averaged $2.3 million.
  • Per our database at Business Quant, Ligand Pharmaceuticals' Cash from Financing Activities crashed by 99800000.0% in 2021 and then skyrocketed by 167187.1% in 2024.
  • Ligand Pharmaceuticals' Cash from Financing Activities (Quarter) stood at $4.2 million in 2021, then tumbled by 227.23% to -$5.3 million in 2022, then skyrocketed by 200.32% to $5.3 million in 2023, then surged by 283.59% to $20.4 million in 2024, then skyrocketed by 1909.25% to $409.6 million in 2025.
  • Its last three reported values are $409.6 million in Q3 2025, $15.0 million for Q2 2025, and -$4.7 million during Q1 2025.